Arthritis News and Research

Latest Arthritis News and Research

Headaches, back pain and arthritis cost companies more than $61 billion per annum

Headaches, back pain, arthritis and other aches distract employees and cost companies more than $61 billion a year in lost productive time, according to a study published in the Journal of the American Medical Association.

1 Oct 2010

Arthritis Foundation applauds House for passing bipartisan arthritis legislation

The Arthritis Foundation applauds the U.S. House of Representatives for passing the Arthritis Prevention, Control and Cure Act (H.R. 1210/S.984), the first comprehensive, bipartisan arthritis legislation in more than 30 years.

1 Oct 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

Women's College to build Ontario's only ambulatory hospital focused on women's health

Women's College Hospital together with The Honourable Deb Matthews, Minister of Health and Long-Term Care, and women representing Ontario's diverse communities, today announced Women's College Hospital is building Ontario's only ambulatory hospital focused on meeting the unique health care needs and priorities of women.

30 Sep 2010

New online CDSMP program launched to battle against chronic illnesses

Taking the battle against the national epidemic of chronic illnesses to the Internet, the National Council on Aging (NCOA) is making Better Choices, Better Health, the online version of the internationally recognized Chronic Disease Self Management Program (CDSMP), available free for people in California and six other states Hawaii, Iowa, Maine, Massachusetts, New Jersey, and Oregon.

30 Sep 2010

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

Three grants totaling more than $4.5 million, from agencies of the National Institutes of Health, will be used to explore novel treatment strategies for muscular dystrophy.

30 Sep 2010

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

Santarus, Inc. and Cosmo Pharmaceuticals S.p.A. today announced positive top-line results from the Phase III clinical study conducted in the U.S. and India to evaluate the safety and efficacy of budesonide MMX® for the induction of remission of mild or moderate active ulcerative colitis. The study results show that budesonide MMX 9 mg taken once daily met the primary endpoint of superiority to placebo.

30 Sep 2010

Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib

Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.

29 Sep 2010

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes.

29 Sep 2010

Inefficiencies in treatment of chronic pain increases healthcare costs and prolongs patient suffering

A new report launched today in the European Parliament shows inefficiencies in the treatment of chronic pain result in increasing healthcare costs and prolonged patient suffering.

29 Sep 2010

Florida likely to seek waiver on medical loss ratio; Ariz. cuts back Medicaid benefits

The Hill Healthwatch: "Florida's 14-member insurance advisory board has unanimously passed a resolution to seek a waiver from the health law's medical loss ratio. An official with the Florida Office of Insurance Regulation tells The Hill that the board's vote means it's a 'done deal' that the state will formally seek some kind of waiver but the board is gathering public input through Oct. 8.

29 Sep 2010

Scientists use turmeric extract to target cancer cells

Scientists at the University of Leicester, funded by Hope Against Cancer, are pioneering the use of a common curry cooking ingredient to target cancer cells. The research in the University Department of Cancer Studies and Molecular Medicine is making use of actual tissue from tumours extracted from patients undergoing surgery.

29 Sep 2010

Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study

A study conducted at Copenhagen University Hospital showed that treatment of rheumatoid arthritis (RA) with disease modifying antirheumatic drugs (DMARDs), glucocorticoids, biologic agents, or a combination of agents significantly reduced radiographic evidence of joint destruction, with a relative effect of 48%-72% as compared with placebo.

29 Sep 2010

Further trials needed to determine clinical application of Abatacept in SLE

Results from a 12-month multi-center clinical trial did not show therapeutic benefit of abatacept over placebo in patients with non-life threatening systemic lupus erythematosus (SLE). Abatacept failed to prevent new disease flares in SLE patients tapered from corticosteroids in an analysis where mild, moderate and severe disease flares were evaluated together. Full details of the phase IIb clinical trial are published in the October issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

29 Sep 2010

Researchers find genetic variants that cause arthritis in breast cancer patients taking aromatase inhibitors

Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear today in the online issue of Journal of Clinical Oncology.

28 Sep 2010

Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients

Galapagos NV announced today that it has started a Phase II clinical study for the Company's flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis. In this clinical trial, the safety and efficacy of this novel candidate drug will be tested in RA patients. Galapagos plans to announce interim results by the middle of next year and complete the trial by the end of 2011.

28 Sep 2010

Bayer’s new oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved a new oral contraceptive, Beyaz (drospirenone / ethinyl estradiol / levomefolate calcium tablets and levomefolate calcium tablets).

28 Sep 2010

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Chelsea Therapeutics International, Ltd. has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an inadequate response to MTX treatment.

27 Sep 2010

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

ISTA Pharmaceuticals, Inc. today highlighted results from the Company's REMURA (bromfenac ophthalmic solution for dry eye) Phase 2 clinical study.

27 Sep 2010

Study finds increasing number of elderly people are prone to celiac diseases

Working to solve the puzzle of when people develop celiac disease has led researchers from the University of Maryland School of Medicine Center for Celiac Research to some surprising findings. They have found that the autoimmune disorder is on the rise with evidence of increasing cases in the elderly.

27 Sep 2010

Arthritis News and Research

Latest Arthritis News and Research

Headaches, back pain and arthritis cost companies more than $61 billion per annum

Arthritis Foundation applauds House for passing bipartisan arthritis legislation

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Women's College to build Ontario's only ambulatory hospital focused on women's health

New online CDSMP program launched to battle against chronic illnesses

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

Inefficiencies in treatment of chronic pain increases healthcare costs and prolongs patient suffering

Florida likely to seek waiver on medical loss ratio; Ariz. cuts back Medicaid benefits

Scientists use turmeric extract to target cancer cells

Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study

Further trials needed to determine clinical application of Abatacept in SLE

Researchers find genetic variants that cause arthritis in breast cancer patients taking aromatase inhibitors

Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients

Bayer’s new oral contraceptive receives FDA approval

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

Study finds increasing number of elderly people are prone to celiac diseases

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Arthritis News and Research

Latest Arthritis News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in